Statements (67)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
ZyVersa_Therapeutics
|
| gptkbp:businessModel |
strategic partnerships
biopharma development |
| gptkbp:CEO |
Kevin_J._McCormack
|
| gptkbp:clinicalTrials |
ongoing
Phase 1 TCR-T cell therapy safety and efficacy Phase 1 and Phase 2 adaptive trials secured funding achieved key endpoints promising efficacy regularly published results multiple_sites_in_the_US |
| gptkbp:collaboratedWith |
biopharmaceutical companies
|
| gptkbp:collaboratesWith |
academic institutions
|
| gptkbp:communityEngagement |
patient advocacy groups
|
| gptkbp:communityOutreach |
educational programs
|
| gptkbp:communityPartnerships |
collaborative studies
|
| gptkbp:communitySupport |
engagement with local organizations
|
| gptkbp:customerFeedback |
integrated into development
|
| gptkbp:deathDate |
TCR-T therapy
|
| gptkbp:develops |
T cell therapies
|
| gptkbp:employeeCount |
growing team
|
| gptkbp:financialPerformance |
patents on T cell therapies
|
| gptkbp:focusesOn |
cell therapy
|
| gptkbp:founded |
2015
|
| gptkbp:funding |
Series A
|
| gptkbp:futurePlans |
expand into new therapies
|
| gptkbp:hasPopulation |
diverse demographics
|
| gptkbp:hasPrograms |
experts in immunotherapy
|
| gptkbp:hasResearchInterest |
cancer treatment landscape
|
| gptkbp:headquarters |
gptkb:Houston,_Texas
|
| gptkbp:healthcare |
focus on quality of life
|
| gptkbp:historicalResearch |
innovative approaches to treatment
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alaunos Therapeutics
|
| gptkbp:impact |
personalized medicine
|
| gptkbp:investmentFocus |
venture capital
institutional investors transparent communication |
| gptkbp:keyIssues |
genetically engineered T cells
|
| gptkbp:market |
immuno-oncology
emerging leader in biotech. |
| gptkbp:marketSegment |
targeted therapies
|
| gptkbp:mission |
improve patient outcomes
|
| gptkbp:partnerships |
gptkb:National_Cancer_Institute
research collaborations biotech collaborations |
| gptkbp:regulatoryCompliance |
gptkb:FDA
adheres to guidelines IND_applications |
| gptkbp:research |
government grants
|
| gptkbp:research_areas |
solid tumors
|
| gptkbp:researchFocus |
oncology
|
| gptkbp:researchInterest |
peer-reviewed journals
advancing cancer therapies leading research institutions |
| gptkbp:strategicGoals |
expand clinical pipeline
|
| gptkbp:targetMarket |
cancer patients
|
| gptkbp:technology |
cutting-edge research
T cell receptor technology cell engineering techniques |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
clinical and preclinical programs
|
| gptkbp:website |
www.alaunostherapeutics.com
|